A role for the GDAP1 gene in the molecular pathogenesis of Charcot-Marie-Tooth disease by Rzepnikowska, Weronika & Kochański, Andrzej
©
 20
18
 b
y 
Ac
ta
 N
eu
ro
bi
ol
og
ia
e E
xp
er
im
en
ta
lis
A role for the GDAP1 gene in the molecular 
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In 2002 a series of mutations in the GDAP1 gene were reported in patients suffering from Charcot‑Marie‑Tooth disease manifesting 
as early–onset, progressive distal‑muscle wasting and weakness. The molecular etiology of Charcot‑Marie‑Tooth ‑GDAP1 disease has 
been elucidated but its pathogenesis remains unclear, especially given the seemingly contradictory function of the GDAP1 protein. 
Expression of GDAP1 is observed almost exclusively in neuronal cells, however, the GDAP1 protein is present in mitochondria, where it 
plays a role in fission, a ubiquitous process occurring in all cells. While GDAP1 contains two glutathione S‑transferase (GST) domains, 
its GST activity is in fact very limited. Additionally, despite GDAP1 affecting mitochondrial functionality, and hence being of great 
importance to cellular function, the GDAP1‑associated Charcot–Marie–Tooth disease is mainly characterized by axonal degeneration. 
Finally, mutations in the GDAP1 gene may be inherited in a recessive or dominant manner. Given the way such varied observations are 
hard to reconcile with one another, the investigation of GDAP1 is at one and the same time a difficult but also challenging endeavour. 
The purpose of this review is to summarize the current knowledge on the GDAP1 protein and its function in the cell. A further part is 
the characterization of GDAP1‑associated Charcot–Marie–Tooth disease, its symptoms and course, as well as an outlining of the possible 
mechanisms underpinning the disorder.
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INTRODUCTION
Charcot‑Marie‑Tooth disease (CMT) is characterized 
by progressive weakness and muscle atrophy (mainly 
encompassing the distal muscles of the upper and low‑
er limbs) and sensory loss. In general terms, CMT is di‑
vided into two main groups i.e. CMT1, which is a demy‑
elinating form associated with reduced nerve‑conduc‑
tion velocities and segmental demyelination and remy‑
elination, and CMT2, axonal neuropathy, characterized 
by axonal loss without demyelinating lesions (Dyck and 
Lambert 1968). The basic criterion for CMT1/CMT2 di‑
vision is the value of 38 m/s of the nerve conduction 
velocity in the motor fibers of the median nerve.
While CMT is caused by mutations in many genes 
involved in various cellular pathways, the different 
mutations in the GDAP1 (ganglioside induced differen‑
tiation associated protein 1) gene are associated with 
an axonal or intermediate form of CMT with recessive 
or dominant modes of inheritance and a wide range of 
severities (Cassereau et al. 2011). The locus for CMT as‑
sociated with GDAP1 gene mutations was first identified 
in cases of recessive CMT in Tunisian families, on chro‑
mosome 8q13‑q21 (Ben Othmane et al. 1993). The cor‑
responding gene was found in 2002 by two independent 
groups (Baxter et al. 2002, Cuesta et al. 2002). In 2005 
the first dominantly‑inherited mutation in the GDAP1 
gene was reported (Claramunt et al. 2005).
GDAP1 protein is involved in many aspects of mi‑
tochondrial morphology and functioning, thus its as‑
sociations with CMT disease is not very surprising, as 
several neurodegenerative diseases result from alter‑
ations in mitochondrial dynamic processes (Bertholet 
et al. 2016, Gao et al. 2017). For example, mutations in 
the mitofusin 2 (MFN2) gene, encoding protein required 
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for mitochondrial fusion (Chen et al. 2003, Santel and 
Fuller 2001), lead to autosomal‑dominant CMT (Züch‑
ner et al. 2004); while mutations in the gene encoding 
optic atrophy protein 1 (OPA1), the main mediator of 
inner membrane fusion in mammals, promote autoso‑
mal‑dominant optic atrophy (ADOA), an inherited form 
of optic‑nerve degeneration (Alexander et al. 2000, 
Delettre et al. 2000).
GDAP1 protein seems to be a very interesting object 
for study in terms of structure and function. Certain of 
its aspects are still unexplored and wait for discovery and 
others are confusing, as some of published reports appear 
contradictory. This review has therefore sought to bring 
together pieces of knowledge concerning the function 
of the protein and its involvement in the appearance of 
CMT. Every effort is also made to shed light on the possi‑
ble molecular mechanism underpinning GDAP1‑neuropa‑
thy, with some indications given as to processes capable 
of contributing to progression of the disease.
The GDAP1 gene and its protein
The GDAP1 gene was originally identiﬁed as one of 
10 cDNAs whose expression increased upon differenti‑
ation of a neuroblastoma cell line (Liu et al. 1999). It 
spans almost 14 kilobases of genomic DNA, with coding 
sequences consisting of six exons (Cuesta et al. 2002). 
Two transcript variants of GDAP1 produced by alterna‑
tive splicing have been identified. The longer variant 
encodes a 358‑amino acid protein, while transcript 
variant 2 encodes a 290‑amino acid protein shortened 
at the N‑terminal. GDAP1 is mainly expressed in neu‑
rons and, albeit at much lower levels, in Schwann cells 
(Niemann et al. 2005, Pedrola et al. 2005). However, 
rather high level of GDAP1 transcript was also found in 
cancer cell lines of different tissue origin (Ratajews‑
ki and Pulaski 2009). The GDAP1 protein contains two 
glutathione S‑transferase (GST) domains (GST‑N and 
GST‑C) separated by an alpha helical loop (α‑loop), 
a C‑proximal hydrophobic domain (HD1) essential to 
GDAP1‑induced mitochondrial and peroxisomal fis‑
sion, and a C‑terminal transmembrane domain (TMD) 
or tail‑anchor, responsible for the correct locating of 
the GDAP1 protein (Cuesta et al. 2002, Huber et al. 2013, 
2016, Marco et al. 2004, Niemann et al. 2009, Wagner et 
al. 2009) (Fig. 1).
The multiple roles of GDAP1 protein
Once the link between GDAP1 and CMT disease had 
been identified, bioinformatics analysis showed that 
GDAP1 belongs to the glutathione S‑transferase (GST) 
family (Cuesta et al. 2002, Marco et al. 2004). These en‑
zymes catalyze the conjugation of the reduced form of 
glutathione with xenobiotic substrates, the purpose 
being detoxification. However, until very recently, 
considerable efforts to demonstrate GST activity in 
purified GDAP1 had been unsuccessful (Pedrola et al. 
2005, Shield et al. 2006). Recently, theta‑class‑like GST 
activity was clearly demonstrated in the case of the re‑
combinant GDAP1 protein (Huber et al. 2016). It seems, 
that the glutathione‑conjugating activity of GDAP1 is 
regulated by its C‑terminal HD1 domain in an autoin‑
hibitory manner, given that a full‑length protein and 
Fig. 1. Graphic representation of the GDAP1 protein domain structure. The borders of individual domains were determined by reference to the Pfam 
database (http: //pfam.xfam.org). Amino‑acid substitutions found in patients with CMT are indicated. Recessively‑inherited changes are represented in 
black (nonsense) and dark gray (missense), while dominant ones are in light gray. Domains: (GST) glutathione S‑transferase domain; (HD1) hydrophobic 
domain; (TMD) transmembrane domain.
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its fragments deprived of both TMD and HD1 or only 
TMD domain were found to be catalytically inactive in 
vitro (Huber et al. 2016). GDAP1 also regulates cellular 
glutathione content in vivo and protects cells against 
oxidative stress. It was found that Gdap1 is upregulat‑
ed in oxidative‑stress‑resistant mouse neuronal cells. 
Overexpression of Gdap1 increases the total cellular 
glutathione level and protects against endogenous 
oxidative stress caused by glutathione depletion. In 
contrast, Gdap1 downregulation increases the sus‑
ceptibility of mouse neuronal cells against glutathi‑
one reduction (Noack et al. 2012). Together, it seems 
that GDAP1 is regulated by the redox state of the cells. 
It was suggested that GDAP1’s GST domains serve as 
a redox sensor, rather than a bona fide GST enzyme, 
modulating its function by changing its conformation‑
al state upon stimulation (Huber et al. 2016). In line 
with this, glutathione depletion resulted in a marked 
upregulation of Gdap1, whereas increasing the cellular 
glutathione content had the opposite effect in mouse 
neuronal cells (Noack et al. 2012). This offers new in‑
triguing insight into the function and the way GDAP1 
activity is regulated.
The finding that GDAP1 is an integral membrane 
protein of the outer mitochondrial membrane (Nie‑
mann et al. 2005, Pedrola et al. 2005) pointed to an 
involvement of the protein in mitochondrial process‑
es. Neurons are extremely polarized cells demanding 
a high level of energy that mitochondria are able to 
provide through adenosine triphosphate (ATP) pro‑
duction induced by the process of oxidative phos‑
phorylation (OXPHOS). Mitochondria are essential 
to neuronal function and involved in many neuronal 
processes, such as calcium (Ca2+) homeostasis, main‑
taining plasma membrane potential, axonal and den‑
dritic transport, and the release and reuptake of neu‑
rotransmitters at synapses (Sheng and Cai 2012, Vos et 
al. 2010). The production of an extra protein regulat‑
ing mitochondrial functionality thus seems explicable 
and understandable enough. This led to a presenta‑
tion of GDAP1 as a participant in the mitochondrial 
ﬁssion process (Niemann et al. 2005, 2009). Overex‑
pression of GDAP1 induces fragmentation of mitochon‑
dria while not inducing apoptosis, the effect being to 
impair mitochondrial transmembrane potential, or to 
interfere with mitochondrial fusion (Niemann et al. 
2005). In Drosophila melanogaster, Gdap1 RNAi leads to 
progressive aggregation and fusion of mitochondria, 
and eventually to the presence of large, elongated mi‑
tochondria in the fly’s thorax muscle. Mitochondria 
in the retina are also of larger size. In turn, smaller 
mitochondria in the retina and, more evidently, in the 
muscle were observed after overexpression of Gdap1 
(López Del Amo et al. 2015). However, GDAP1 would 
not seem to be a canonical ﬁssion protein, as its ho‑
mologues have not been found in either Saccharomyces 
cerevisiae or Caenorhabditis elegans (López Del Amo et 
al. 2015), albeit with the expression of human GDAP1 
being in a position to correct for deﬁciency in yeast 
FIS1 (Estela et al. 2011). What is more, GDAP1‑fission 
is seen to depend on the other well‑known ﬁssion fac‑
tors Fis1 and Drp1 (Niemann et al. 2009). These find‑
ings can be put together with reports that overexpres‑
sion of CMT‑patient missense mutant alleles results in 
fragmented mitochondrial distribution very similar to 
that found in cells overexpressing the wild‑type allele 
(Pedrola et al. 2008, Pla‑Martín et al. 2013). That gives 
rise to a suggestion that GDAP1 rather have another 
function than mitochondrial fission per se.
Some clue as to the actual role of GDAP1 in cells 
is provided by a recent report revealing that GDAP1 
is present not only in mitochondria, but also in mi‑
tochondria‑associated membranes (MAMs), a place of 
interface of mitochondria and endoplasmic reticulum 
(ER) (Pla‑Martín et al. 2013). Formation of the con‑
tact sites between ER and mitochondria seems to be 
required not only for the regulation of mitochondri‑
al morphology, dynamic and function, but also for the 
transport of calcium from the ER to the mitochondria, 
the import of lipids into mitochondria, the formation 
of autophagosomes, and cell survival (Herrera‑Cruz 
and Simmen 2017, Vance 2014). The ER has been shown 
to wrap around mitochondria and to facilitate mito‑
chondrial division, and this step precedes Drp1 recruit‑
ment (Friedman et al. 2011). GDAP1 may be involved 
in the formation and/or modulation of the ER‑mito‑
chondria contacts and this way regulate the fragmen‑
tation of mitochondria, especially that GDAP1 fission 
is Drp1‑dependent (Niemann et al. 2009). Depletion of 
GDAP1 leads to changes in the mitochondrial network, 
reducing co‑localization between mitochondria and 
ER and limiting Ca2+ entry in mitochondria following 
store‑operated calcium entry (SOCE) in human neu‑
roblastoma cells (Pla‑Martín et al. 2013). Consistently, 
overexpression of GDAP1 in HeLa cells is seen to induce 
a redistribution of mitochondria that show increased 
contacts with ER (Pla‑Martín et al. 2013). Defects in 
the maintenance of intracellular Ca2+ homeostasis were 
also observed in gdap1‑/‑ mice neurons (Barneo‑Muñoz 
et al. 2015).
As GDAP1 interacts with trafﬁcking‑associated pro‑
teins (caytaxin and RAB6B) and β‑tubulin (Estela et 
al. 2011, Pla‑Martín et al. 2013), it may form contacts 
between mitochondria and microtubules and direct‑
ly participate in mitochondrial transport. Abnormal 
post‑translational modifications of microtubules were 
observed in primary sensory and motor neuron cul‑
tures of gdap1‑/‑ mice (Barneo‑Muñoz et al. 2015). Also, 
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Gdap1 RNAi at the retina of Drosophila melanogaster re‑
sults in a tendency for peripheral localization of mito‑
chondria to be lost (López Del Amo et al. 2015). In more 
complex polarized cells such as neurons, mitochondria 
are the subject of active transport to synaptic regions, 
which have high demands for energy and calcium buff‑
ering. This means that the expression of additional 
protein like GDAP1 facilitating this process is highly 
probable.
Beyond its involvement in mitochondrial process‑
es, GDAP1 also targets peroxisomes to regulate peroxi‑
somal morphology. Loss of GDAP1 leads to elongated 
peroxisomes, whereas overexpression promotes per‑
oxisomal fragmentation. Like mitochondrial fission, 
GDAP1‑induced fission of peroxisomes is Drp1‑depen‑
dent (Huber et al. 2013).
To sum up, however the precise molecular func‑
tion of GDAP1 is unclear, the available data indicate an 
important role of GDAP1 in several key cellular pro‑
cesses, like maintenance of mitochondrial morpholo‑
gy, motility, distribution and functioning, as well as 
in the cellular homeostasis of Ca2+ and glutathione. It 
is likely that GDAP1 interacts with different protein 
partners and is responsible for formation of the con‑
tacts between mitochondria or peroxisomes and other 
cellular structures, like ER and microtubules. These 
interactions are extremely important for correct mi‑
tochondrial/peroxisomal functioning and dynamics 
and also prevent the damage to mitochondria and 
stress resulting from it. Thus it is not surprising that 
the neurons relying heavily upon energy generated by 
mitochondria are cells which are most affected by mu‑
tations of GDAP1.
CMT disease is caused by mutations in the GDAP1 
gene
As shown above, GDAP1 is involved in the regulation 
of the key cellular processes that neuronal cell viability 
and survival entail. It is not surprising, therefore, that 
mutations in the gene encoding this protein may lead 
to pathological defects. Indeed, changes in the GDAP1 
gene are associated with CMT disease, one of the he‑
reditary motor and sensory neuropathies, character‑
ized by progressive sensory deﬁciency and distal pro‑
gressive muscle debility. To date, above 80 mutations 
associated with the GDAP1 gene have been described 
(http: //www.hgmd.cf.ac.uk/ac/index.php). Most are 
missense/nonsense mutations (Fig. 1), though some 
small deletions, insertions and mutations interfering 
with splicing have also been reported (Auer‑Grumbach 
et al. 2008, Cuesta et al. 2002, De Sandre‑Giovannoli et 
al. 2003, Kabzińska et al. 2005, Nelis et al. 2002).
CMT disease phenotypes associated with GDAP1 
mutations
GDAP1 mutations are responsible for primary ax‑
onal damage, however in sural biopsies specimens 
obtained from some patients harboring GDAP1 gene 
mutations additional dysmyelination has also been de‑
tected (Kabzinska et al. 2006, Fu et al. 2017). Pheno‑
type‑genotype correlations for mutations are hard to 
determine for several reasons. Firstly, patient sympto‑
mology is very diverse. In some cases, especially con‑
sidering dominantly‑inherited GDAP1 mutations, there 
is marked variability for age of onset and the level of 
functional disability in patients carrying the same mu‑
tations, as well as significant intra‑familial variability 
(Azzedine et al. 2003, Manganelli et al. 2012). Secondly, 
the majority of mutations have been described in only 
a few unrelated patients (Cassereau et al. 2011). Final‑
ly, it is possible that other genes mutations may act as 
modulators of the disease phenotype. A recent finding 
of this kind concerned the possible contribution of the 
JPH1 Arg213Pro allele to CMT, with the GDAP1 mutation 
resulting R120W responsible for more severe clinical 
manifestations (Pla‑Martín et al. 2015). However, it is 
clear that the autosomal recessive (AR) and autosomal 
dominant (AD) forms of CMT (GDAP1) show numerous 
distinct clinical and electrophysiological features. In 
the AR form penetrance of the GDAP1 gene mutations is 
complete and there is rather small inter‑ and intra‑fa‑
milial variability. This form is usually severe with early 
onset (symptoms are usually observed before the end 
of adolescence) and is characterized by muscle weak‑
ness and wasting resulting in disabilities in the first 
or second decade of life (Cassereau et al. 2011). Some 
patients with the AR trait of inheritance additionally 
manifest dysphonia and respiratory dysfunction (Se‑
villa et al. 2008, Sivera et al. 2017). Among the reces‑
sively‑inherited changes, nonsense and frameshift 
mutations leading to the truncation of the protein 
produced are very often associated with a most severe 
phenotype of CMT showing a more‑rapid course of the 
disease (Cassereau et al. 2011). In turn, it is common for 
dominantly‑inherited mutations to be associated with 
late‑onset and rather mild CMT. Of note, in the group 
of patients harbouring dominant GDAP1 gene muta‑
tions (AD‑CMT) the penetrance at least at the clinical 
level seems to be limited, but minimal electrophysi‑
ological abnormalities may be observed almost in all 
clinically asymptomatic individuals. Similarly, in some 
of the clinically asymptomatic individuals harbouring 
GDAP1 gene mutations, some abnormalities may be de‑
tected in the feet and distal leg muscles (Cassereau et 
al. 2011, Manganelli et al. 2012, Sivera et al. 2017, Zi‑
mon et al. 2011) (Fig. 2).
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A model organism to investigate the function 
of GDAP1 and GDAP1‑related CMT diseases
Some challenges have been experienced identifying 
a suitable model to study GDAP1 protein function and the 
pathomechanisms leading to CMT. As mentioned above, 
GDAP1 genes are not found in simple model organisms 
like the yeast Saccharomyses cerevisiae and the nematode 
Caenorhabditis elegans. On the other hand, work does show 
that human GDAP1 complements almost all phenotypes 
involving deletion of the FIS1 gene in yeast (Estela et al. 
2011). This opens up a new possibility for S.cerevsiae to be 
used in in vivo testing of the potential pathogenicity of 
the mutations found in human beings. However, neurons 
are very complex cells with high demands where ener‑
gy and transport are concerned. This means that results 
obtained in yeast may not offer a full reflection of the 
conditions the neuronal cells experience.
Recently, a true GDAP1 ortholog was confirmed in 
Drosophila melanogaster, with alterations in the level of 
Fig. 2. Clinical presentation of CMT disease caused by GDAP1 mutations varies from a mild form (A) via a moderate form (B) to a severe form (C). In patient 
(A), CMT disease is inherited as an autosomal‑dominant trait, whereas the (B) and (C) patients suffer from a recessive type of CMT. Note the varying 
degrees of distal‑muscle wasting of the upper and lower limbs. (D) Scheme of clinical characteristics of CMT caused by mutations in GDAP1 gene.
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Gdap1 in specific tissues found to lead to neuronal and 
muscular degeneration. Importantly, co‑expression of 
human GDAP1 with Gdap1 RNAi can correct the neuro‑
degenerative phenotype in the retina (López Del Amo 
et al. 2015). However, it is noteworthy that muscular 
degeneration in Drosophila is tissue‑autonomous and 
not dependent on innervation, which is not observed in 
patients (López Del Amo et al. 2015). This may be a re‑
sult of an expression pattern different from that found 
in human beings, as expression of Gdap1 was also ob‑
served in fly muscle (López Del Amo et al. 2015). In line 
with this, general alteration of the level of Gdap1 has 
severe consequences, such as a reduction in maximum 
lifespan, not only resulting from impaired neuromus‑
cular competence (López del Amo et al. 2017).
Thus far, two mouse models lacking Gdap1 (gdap1‑/‑) 
have been reported. They present different pheno‑
types, though in both cases Western blot analysis 
confirmed the absence of GDAP1 protein. In the first 
model, 19‑month‑old Gdap1 knockout mice lacking 
exon 5 develop a peripheral neuropathy with reduced 
nerve‑conduction velocity and mild hypomyelination, 
but no detectable axonal loss (Niemann et al. 2014). In 
contrast, in the second mouse model, involving the de‑
letion of exon 1 from the Gdap1 gene, no evident signs 
of demyelination were observed despite the occur‑
rence of motor behavioural deficits from 3 months of 
age. This model also lacks evidence of morphological 
axonopathy, though proteomic studies of energetic me‑
tabolism in peripheral nerves reveal some physiologi‑
cal damage. Some changes have also been observed in 
motor neuron somas and at neuromuscular junctions 
(Barneo‑Muñoz et al. 2015). Of note, mutations in the 
GDAP1 gene of patients are associated predominantly 
with the axonal form of CMT (Cassereau et al. 2011), 
what is not observed in both mouse models. Also, it is 
unclear why the results presented in these two studies 
are so different, since they investigate the same phe‑
nomenon, at least in theory.
Summarizing, the use of model organisms to 
study the function of GDAP1, and the pathogene‑
sis of GDAP1‑related CMT, has obvious limitations. In 
less‑complex organisms, such as yeast and nematode 
worms, orthologs of the GDAP1 gene are not observed. 
While this fact does not preclude their use, it does ne‑
cessitate painstaking investigations of appropriate 
phenotypes, which may prove unsuccessful. On the 
other hand, in the more complex organism, some fea‑
tures of CMT disease do indeed present, and are with‑
out doubt informative and helpful. However, they can‑
not be said to offer an exact reflection of phenotypes 
observed in patients. Some important data regarding 
the mechanism behind GDAP1‑associated CMT may thus 
be lacking, while others may not relate to human cells.
The role of GDAP1 gene mutations in CMT 
pathogenesis
The GDAP1 protein regulates many key aspect of 
neuronal function and is responsible for maintenance 
of bioenergetic homeostasis. Many processes requir‑
ing GDAP1 are interconnected and affect one other. 
Thus, the pathogenic mechanism of GDAP1 mutations 
found in patients with CMT may involve many multi‑
ple pathways and minor defects, in the end, leading to 
CMT disease. Mutations in the GDAP1 gene may be in‑
herited dominantly or recessively and these two traits 
are characterized by distinct phenotypes. It seems rea‑
sonable to suggest that the mechanisms underpinning 
the dominantly‑ and recessively‑inherited mutations 
are different. In the following sections we provide an 
overview on the potential pathological mechanisms as‑
sociated with different GDAP1 mutations, according to 
inheritance trait.
GDAP1 gene mutations transmitted as 
an autosomal‑recessive trait
It is usual for recessively‑inherited mutations to be 
associated with a loss‑of‑function phenotype, where 
two genomic copies of the given gene are inactive and 
the protein cannot perform its function. This is ob‑
served in the case of complete deletion of the genes, 
mutations leading to the appearance of the premature 
STOP codon (nonsense, insertions, deletions) or mis‑
sense mutations which significantly impair protein 
function. Similarly, we can expect mutations transmit‑
ted in a recessive mode in the GDAP1 gene to caused 
dysfunction of the protein resulting in CMT pheno‑
types. Indeed, those mutations, which lead to a pre‑
mature stop of translation or which are present within 
the C‑terminal tail of GDAP1, the mitochondrial and 
peroxisomal targeting domain, affect anchoring to 
the mitochondrial outer membrane, or destabilize the 
protein, resulting in its rapid degradation and causing 
the most severe forms with disease onset in the ﬁrst 
decade of life (Cassereau et al. 2011, Kabzińska et al. 
2011, Niemann et al. 2005). The situation is less obvious 
for the missense mutations, which constitute the ma‑
jority of those described so far. We cannot exclude the 
possibility that some also provoke rapid degradation of 
the mutant protein. It was noted that, unlike wild‑type 
recombinant GDAP1 protein, all tested mutants iso‑
lated from insect cells were non‑soluble, suggesting 
non‑functional folding (Huber et al. 2016). Neverthe‑
less, we cannot compare the heterologous production 
of the recombinant protein with the situation in the 
native host cell, with this observation supporting the 
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idea of inactivation and very rapid degradation of the 
mutant GDAP1 protein through multiple protein quali‑
ty‑control systems.
GDAP1 regulates several aspects of mitochondri‑
al dynamics. Impaired mitochondrial fission may be 
a candidate mechanism underlying GDAP1‑associat‑
ed axonopathy. Mitochondrial division facilitates the 
transport, distribution, and quality control‑mediated 
degradation of the organelle. The balance between 
mitochondrial division and fusion is required to main‑
tain the form and function of mitochondria and thus 
neuronal viability and survival (Lackner 2014, Safiulina 
and Kaasik 2013). Nevertheless, data on fission activity 
of particular GDAP1 mutant proteins is contradictory. 
Some reports indicate that recessively‑inherited muta‑
tions in the GDAP1 gene result in reduced fission activi‑
ties (Niemann et al. 2005, 2009, Noack et al. 2012), while 
others have shown overexpression of missense mutant 
alleles resulting in a fragmented mitochondrial distri‑
bution very similar to that found in cells overexpress‑
ing the wild‑type allele (Pedrola et al. 2008, Pla‑Martín 
et al. 2013). However, not all recessively‑inherited mu‑
tations would seem to impair the GDAP1 fission‑activi‑
ty to the same degree (Niemann et al. 2005, Noack et al. 
2012), suggesting something other than loss‑of‑func‑
tion mechanisms or impairment of other aspects of mi‑
tochondrial functioning.
Disrupted transport of mitochondria offers a very 
potent mechanism which may account for axonal loss 
in CMT patients with GDAP1 mutations. As was men‑
tioned above (under, The multiple roles of GDAP1 pro‑
tein), GDAP1 may play a direct role in the active trans‑
port of mitochondria inside neuronal cells. Thus, mu‑
tations may alter the interaction between GDAP1 and 
transport protein, leading to alterations in mitochon‑
drial transport and movement. Missense mutations are 
clustered predominantly in two regions: the α‑loop be‑
tween two GST domains and the GST‑C domain (Fig. 1). 
The α‑loop region is responsible for the interaction 
between GDAP1 and β‑tubulin (Estela et al. 2011), per‑
haps suggesting that changes here at least may impair 
the interaction between the two. Indeed, mutant pro‑
teins have been shown to interact more strongly with 
β‑tubulin than does the wild‑type protein, with the in‑
teraction being more intense for those mutations lo‑
cated within or near the α‑loop domain (Estela et al. 
2011). Interactions between GDAP1 and transport pro‑
teins are also most likely required as mitochondria are 
being located close to SOCE sites. Their perturbation 
by mutations in GDAP1 is probably responsible for the 
inhibition of SOCE activity, as recessively‑inherited 
GDAP1 mutations located inside the α‑loop are unable 
to compensate for a lack of GDAP1 in SOCE activity in 
human neuroblastoma cells (González‑Sánchez et al. 
2017). Additionally, research using yeast S. cerevisiae 
makes it clear that GDAP1 alleles containing missense 
mutations rescue all phenotypes of the null FIS1 (fis1Δ) 
mutant, except for cell‑cycle delay; and this effect is 
independent of the inheritance pattern of particular 
mutations. The authors thus propose that the defect 
in the cell cycle in the fis1Δ strain may be a result of 
an anomalous interaction between mitochondria and 
microtubules of the mitotic spindle (Estela et al. 2011). 
What is interesting, similar effect may be observed in 
mammalian cells, as significant down‑regulation of cell 
cycle pathways and G2/M growth arrest in Gdap1‑null 
mouse cells undergoing reprogramming were described 
(Prieto et al. 2016). In neurons, which are highly com‑
plex cells, mitochondria must be transported actively 
to (and maintained in) regions requiring a high ener‑
gy level, like synapses. The movement of mitochondria 
is modulated in response to physiological signals and 
directed at dendrites and axons, i.e. sites that are far 
from the cell bodies (Schwarz 2013). Transport of mi‑
tochondria is so crucial in determining neuronal sur‑
vival that a disruption of the synaptic translocation of 
mitochondria affects neuronal function adversely (Li et 
al. 2004, Verstreken et al. 2005). Axonal transport de‑
fects are further shown to play an important role in the 
pathology of neurodegenerative disorders (Millecamps 
and Julien 2013) and neuropathies. Mutations in MFN2 
gene, encoding mitochondrial fusion protein, MFN2 re‑
semble those in GDAP1 in also being implicated in the 
appearance of CMT (Züchner et al. 2004). An abnormal 
mitochondrial distribution was observed in the Purkin‑
je cells of Mfn2‑deﬁcient mice (Chen et al. 2007). Also, 
the accumulation of mitochondria in the distal part of 
sural nerve axons has been observed in CMT patients 
with MFN2 mutations (Vallat et al. 2008), while MFN2 is 
found to interact with the Miro/Milton complex, which 
in turn links mitochondria to kinesin motors (Misko et 
al. 2010). All these ﬁndings suggest that impairment of 
mitochondrial transport may be the key mechanism in‑
volved in the pathophysiology of the MFN2‑dependent 
CMT. Additionally, MFN2 mutants can cause degenera‑
tion speciﬁc to long motor and sensory axons only, as 
these highly metabolic regions are most distant from 
the cell body, and thus more sensitive to impaired mi‑
tochondrial recruitment (Misko et al. 2010). It is prob‑
able that similar mechanism is responsible for the axo‑
nopathy in GDAP1‑related CMT and this is the one of the 
main reasons of axons injury and death.
As GDAP1 is involved in many aspects of mitochon‑
drial functioning, we cannot preclude other factors 
contributing to or modulating the symptoms of CMT 
disease. The alteration of the mitochondrial network 
and calcium homeostasis caused by decreased level of 
GDAP1 may also disturb the autophagy flux (Haidar and 
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Timmerman 2017). Autophagy is a degradation pro‑
cess required for the removal of proteins aggregates, 
superfluous or damaged organelles and other dysfunc‑
tional cells components. Neuronal cells are especially 
sensitive to disruption of the autophagic pathways and 
defects in this process are observed in many neurode‑
generative diseases, also in hereditary neuropathies 
(Haidar and Timmerman 2017). Thus, deregulation of 
autophagy in GDAP1‑deficient cells may also contrib‑
ute to the pathology of CMT.
It is well known that mitochondria are producers of 
reactive oxygen species (Murphy 2009), with impair‑
ment of function leading to increased generation of 
oxygen radicals, highly reactive molecules interacting 
with and damaging nucleic acids, proteins, carbohy‑
drates and lipids. Oxidative stress accompanies many 
neurodegenerative diseases (Chen et al. 2012) and mi‑
tochondrial diseases (Hayashi and Cortopassi 2015). In‑
deed, some reports suggest an involvement of oxidative 
stress in the development of CMT, since fibroblasts from 
autosomal‑recessive CMT patients with reduced GDAP1 
levels also have reduced glutathione concentration 
and reduced mitochondrial membrane potential (No‑
ack et al. 2012). Additionally, mutations cluster with‑
in the coding region of the GST‑C domain, suggesting 
that the function of GDAP1’s GST domain is impaired 
in these mutants. Mild but persistent oxidative‑stress 
conditions in Gdap1‑/‑ mice have also been document‑
ed (Niemann et al. 2014). On the other hand, metabolic 
analysis in Drosophila melanogaster suggests that alter‑
ations in oxidative stress are not a primary cause of the 
neuromuscular degeneration, but a long‑term conse‑
quence of the underlying mitochondrial dysfunction 
(López Del Amo et al. 2015). Consistently, short‑term 
knockdown of GDAP1 is not shown to affect intracellular 
glutathione levels, or cause oxidative stress in mouse 
neuroblastoma cells (Huber et al. 2013). As the involve‑
ment of the reactive oxygen species in the CMT disease 
is still being debated, it is possible that they may exac‑
erbate the symptoms, and contribute to a more rapid 
course of the disorder.
The recent finding that GDAP1 is also associated 
with MAM (see, The multiple roles of GDAP1 protein) 
gives the possibility that the defects described above 
may result from alteration in formation or functioning 
of the ER‑mitochondria contacts. Several key cellular 
processes are regulated by MAM including lipid metab‑
olism, calcium homeostasis, mitochondrial fission‑fu‑
sion events, transport of mitochondria and autophagy 
(Krols et al. 2016). Thus, it is not surprising that several 
proteins associated with these junctions are involved 
in neurodegeneration (Krols et al. 2016). However, this 
aspect of GDAP1 functioning is unclear and need fur‑
ther extensive studies.
GDAP1 gene mutations transmitted as 
an autosomal‑dominant trait
Dominantly‑inherited mutations represent a mi‑
nority of all the changes found in the GDAP1 gene. This, 
combined with relatively weak and heterogeneous phe‑
notypes, has meant these mutations are investigated 
less extensively than recessively‑inherited counter‑
parts. The present data do not allow for clear identi‑
fication concerning the dominant mechanism reflects 
haploinsufﬁciency, dominant‑negative loss of activity 
or a toxic function gained. The first option does not 
seem reliable, as the nonsense mutations leading to the 
shortening and inactivation of the protein are reces‑
sively‑inherited. Two other options are more plausible, 
and all the more so given that GDAP1 is able to form 
heterodimers, with the mutations not disturbing pro‑
tein dimerization, irrespective of the mode of inheri‑
tance (Huber et al. 2016). There is thus a possibility that 
mutant proteins may interact with wild‑type ones, giv‑
ing impairment of the overall GDAP1 function.
Like the mutations transmitted in a recessive trait, 
dominant mutations may affect mitochondrial trans‑
port and distribution, and similarly, this may be one 
of the most important mechanisms involved in axo‑
nal loss. However, it seems that dominantly‑inherit‑
ed mutations impair mitochondrial dynamics in oth‑
er way than those inherited recessively. Overexpres‑
sion of the dominant mutant GDAP1 alleles increases 
mitochondrial motility, but – unlike wild‑type or re‑
cessive variants ‑ was not found to induce signiﬁcant 
changes in mitochondria–ER interactions (Pla‑Martín 
et al. 2013). Additionally, these variants promote sig‑
nificantly increased SOCE activity, as compared with 
wild‑type GDAP1 – a fact that might reflect altered 
mitochondrial distribution vis‑à‑vis the plasma mem‑
brane, under base conditions (González‑Sánchez et al. 
2017). Taken together, these results suggest that the 
motility and proper positioning of mitochondria in re‑
spect of plasma membrane are affected. This may lead 
to the impairment of mitochondrial functioning and 
energy production. It was presented that the c.719G > A 
(Cys240Tyr) dominantly‑inherited GDAP1 mutation is 
shown to be associated with impaired activity of mito‑
chondrial complex I (Cassereau et al. 2009). However, 
we cannot preclude that observed defect is indepen‑
dent from mitochondrial transport and additionally 
contributes to the course of the CMT disease. Complex 
I is the largest of the electron transport chain com‑
plexes, and the major site of superoxide production 
(Kudin et al. 2004). Its activity and expression are re‑
duced in many neuronal diseases, such as Parkinson’s 
disease (Parker et al. 2008, Schapira et al. 1990), Leber 
hereditary optic neuropathy (Brown et al. 2000, Kor‑
GDAP1 gene in the pathogenesis of CMT disease 9Acta Neurobiol Exp 2018, 78: 1–13
sten et al. 2010, Wallace et al. 1988) and primary open 
angle glaucoma (Lee et al. 2012, Van Bergen et al. 2015). 
Complex I deﬁciency leads to reduced NADH oxidation 
and electron transfer, causing a sharp reduction in ATP 
synthesis. Decreased energy production may result 
in defects in all highly energy‑consuming processes, 
such as mitochondrial fusion and transport. Indeed, 
dominantly‑inherited mutations in GDAP1 have been 
found to contrast with recessively‑inherited ones, in 
that they impair normal mitochondrial fusion, with 
mild damage to mitochondria sustained in the pro‑
cess (Niemann et al. 2009). Dysfunction of Complex I is 
also associated with increased generation of reactive 
oxygen species, with chronic oxidative stress ensuing. 
This factor may also contribute to the pathogenesis of 
dominantly‑inherited mutations.
The overall disruption of mitochondrial physiology 
as observed in the dominantly‑transmitted mutation 
may lead to increased vulnerability of the cells to apop‑
tosis and necrosis, with axonal loss ensuing. Indeed, 
overexpression of the dominant mutant allele of GDAP1 
was seen to increase sensitivity of cells to apoptosis‑in‑
ducing factors (Niemann et al. 2009).
CMT (GDAP1) pathogenesis – a general view
To sum up, the dominantly‑ and recessively‑in‑
herited mutations appear to be characterized by di‑
verse modes of action, as the mutant alleles behave 
in different ways, depending on the mode of inheri‑
tance. However, both types of mutation may alter the 
Fig. 3. The possible mechanism of axonal damage in CMT patients with GDAP1 mutations.
GDAP1 may be involved in many processes associated with mitochondria, like fission events, the formation of ER‑mitochondria contacts and the transport 
of mitochondria along microtubules (MTs). CMT‑associated GDAP1 mutations may impair each of the events leading to the appearance of general defects 
in mitochondrial functioning as the mitochondrial network is disrupted, interaction between mitochondria and the ER altered, calcium homeostasis 
impaired, ATP synthesis reduced, oxidative stress due to the excessive presence of reactive oxygen species (ROS) increased and axonal transport impaired. 
All of these defects exert a negative influence on the axon, and contribute to axonal damage resulting in CMT disease. Question marks indicate unknown 
elements and/or interacting partners.
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same processes, for example axonal transport, which 
seems to be one of the most important reasons for 
axonal loss. However, in both cases the mechanisms 
underpinning CMT disease are complex and may in‑
clude many pathological events, like disruption of 
the mitochondrial network, altered interactions be‑
tween mitochondria, the ER and microtubules, re‑
duced ATP production and increased oxidative stress 
and impairment of calcium homeostasis (Fig. 3). Be‑
cause all these processes are inextricably linked and 
interdependent, it is hard to say which one indeed 
represents the primary cause of GDAP1‑associated 
CMT. It is possible that all the defects observed in 
cells carrying mutant alleles contribute to the symp‑
toms of the disease and may modulate their severity 
and course. Certain mutations may affect different 
pathway in their own way and observed axonopathy 
is a result of very complex effects. In general, dys‑
function of the GDAP1 protein may lead to overall mi‑
tochondrial impairment. This observation is support‑
ed by a recent study using a model organism. In the 
peripheral nerves of Gdap1‑/‑ mice (as compared with 
wild‑type mice), expression analysis relating to se‑
lected mitochondrial proteins reveals changes in ex‑
pression of all markers of glycolysis, oxidative phos‑
phorylation and mitochondrial dynamics, as well 
as catalase of oxidative stress (Barneo‑Muñoz et al. 
2015). In turn, global proteomic analysis in D. melan‑
ogaster has shown that both up‑ and down‑regulation 
of Gdap1 results in deregulation of the insulin‑sig‑
naling pathway, an accumulation of carbohydrates 
and an increase in the β‑oxidation of lipids, indicat‑
ing changes in energy metabolism that favor the use 
of lipids as an energy source (López del Amo et al. 
2017). Similarly, studies in mouse Mfn2 have revealed 
deffects in mitochondrial functioning, altering glu‑
coneogenesis and impairing insulin signaling in the 
liver and muscle (Sebastián et al. 2012).
CONCLUSIONS
Since the GDAP1 gene is mainly expressed in neu‑
rons, neuronal dysfunction seems a logical conse‑
quence of its depletion or mutation. Indeed, chang‑
es in the GDAP1 gene result in the CMT disease. Our 
basic knowledge about GDAP1 is growing and many 
cellular processes requiring this protein have been 
discovered. Currently, it is known that GDAP1 is not 
only required for fission of mitochondria, but also 
regulates mitochondrial interaction with ER and plas‑
ma membrane, transport, calcium entry, production 
of energy and ROS, and also morphology of peroxi‑
somes. However, many aspects of GDAP1 function 
require further investigation, for example what spe‑
cific role(s) GDAP1 plays in neuronal cells that make 
it an essential requirement for normal functioning 
and alteration of which pathway contributes most to 
phenotypes observed in GDAP1‑depleted cells. Also, 
the mechanism resulting in the dominant or reces‑
sive trait of GDAP1 gene mutations remains unclear, 
especially given the lack of regions in which only the 
one of these two types of mutations is clustered. Both 
types are located in the central part of the protein 
(the α‑loop and GST‑C domain), which may suggest 
that particular mutations affect GDAP1 protein ac‑
tivity in various ways, or impair different functions 
of the protein. Taking these facts into account, it is 
possible that there are many factors contributing and 
modulating the GDAP1‑CMT and each of the mutations 
leads to the disease in a different way, affecting some 
processes more and some less, thereby explaining 
such heterogeneous symptoms, course and severity of 
CMT disease. This may complicate the thinking of any 
future therapy for this disorder. Finally, we cannot 
definitively exclude that the majority of the reported 
so far biochemical and cellular alterations accompa‑
nying GDAP1 mutations reflect not yet identified pri‑
mary disturbances. Despite all the complexity of the 
picture that emerges from the currently available lit‑
erature, there is still a possibility that, at least, some 
GDAP1 gene mutations share a common pathogenic 
pathway, which may represent a potential target for 
CMT therapy.
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